In Vivo Efficacy of Novel Monobactam LYS228 in Murine Models of Carbapenemase-Producing Klebsiella pneumoniae Infection.

Authors :: Weiss WJ
Pulse ME
Nguyen P
Growcott EJ
Source :: Antimicrobial agents and chemotherapy [Antimicrob Agents Chemother] 2019 Mar 27; Vol. 63 (4). Date of Electronic Publication: 2019 Mar 27 (Print Publication: 2019).
Publication Year :: 2019
Abstract: LYS228 has potent antibacterial activity against carbapenem-resistant strains of Enterobacteriaceae LYS228 was efficacious in neutropenic thigh models established with Klebsiella pneumoniae producing KPC-2 or NDM-1; pretreatment with uranyl nitrate considerably shifted calculated static doses of LYS228. In murine ascending pyelonephritis, LYS228 reduced bacterial burden in kidney, urine, and bladder. The successful treatment of murine infection models established with carbapenem-resistant K. pneumoniae further supports the clinical development of LYS228.<br /> (Copyright © 2019 American Society for Microbiology.)

Subjects :: Animals
Carbapenem-Resistant Enterobacteriaceae metabolism
Carbapenems pharmacology
Disease Models, Animal
Female
Klebsiella Infections microbiology
Klebsiella pneumoniae metabolism
Mice
Pyelonephritis drug therapy
Pyelonephritis microbiology
Anti-Bacterial Agents pharmacology
Bacterial Proteins metabolism
Carbapenem-Resistant Enterobacteriaceae drug effects
Klebsiella Infections drug therapy
Klebsiella pneumoniae drug effects
Monobactams pharmacology
beta-Lactamases metabolism

Full Text Access

Tools